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Chlamydia pneumoniae is a Gram-negative obligate intracellular bacterium that causes acute upper and lower
respiratory infections. Its distribution is worldwide. Seroepidemiological studies have shown an association between C.
pneumoniae and atherosclerosis, and the risk of acute myocardial infarction. Several studies had detected C. pneumoniae
in atherosclerotic lesions from coronary and carotid arteries, in abdominal aortic aneurysms (AAA), and in sclerotic
aortic valves. One study consistently succeeded in culturing C. pneumoniae from an atherosclerotic lesion, indicating
the presence of viable organisms. However, the pathogenicity is unknown, and the significance of detecting the organism
is unresolved.
In two minor controlled clinical trials, patients with ischaemic heart disease were randomised into antibiotic-treated
and placebo groups. Both trials showed a significant reduction in serious endpoints in patients receiving macrolide.
Macrolide therapy thus seems to improve the outcome of severe ischaemic heart disease. It is not known whether this is
caused by eradicating C. pneumoniae organisms, or by the macrolide’s non-specific anti-inflammatory effect.
Since both C. pneumoniae and inflammation are found in the AAA wall, it may be considered that macrolide would
also improve the outcome of AAA and other diseases related to vascular surgery. In order to confirm this, randomised
trials with macrolide therapy are needed, as well as diagnostic methods that can differentiate between individuals who
are or are not infected with C. pneumoniae. The latter are needed in order to clarify the impact of the presence of C.
pneumoniae and to avoid indiscriminate use of antimicrobials.
Introduction cause disease in humans: C. trachomatis, which prim-
arily causes trachoma and urogenital infections; C.
Despite efforts to improve antihypertensive and anti- psittaci, causing ornithosis; and C. pneumoniae, involved
hyperlipidaemia treatment, and to encourage smoking in respiratory infections. Chlamydia trachomatis and C.
cessation, changes in dietary habits, and more exercise, psittaci have been known for decades, but C. pneumoniae
atherosclerosis is the main cause of death in the West- was not recognised as a separate species within the
ern world. At present, most medical and surgical Chlamydia genus until 1989.1 To date, only one serotype
treatments for atherosclerosis are palliative. During the of C. pneumoniae has been found. The outer cell mem-
last decade an association has been reported between brane of Chlamydia consists of lipopolysaccharide (LPS)
Chlamydia pneumoniae and atherosclerosis. This bac- that is structurally similar to LPS found in other Gram-
terium can be treated with macrolides and such treat- negative bacteria. The LPS is genus-specific and, there-
ment may have a substantial impact on atherosclerotic fore, identical for all three Chlamydia species. In ad-
manifestations. dition to LPS, several outer membrane proteins
(OMPs) have been demonstrated. One or more OMPThe biology, structure, and effects of C. pneumoniae
is used as a species-specific epitope and can be detected
by monoclonal antibodies.2,3Chlamydia are obligate intracellular Gram-negative
Chlamydia pneumoniae replicates during a biphasicbacteria. Three species within the genus Chlamydia
developmental cycle.3,4 The infective and invasive ele-
mentary body (EB) survives extracellularly and is*Please address all correspondence to: J. S. Lindholt, Laerkevej 11,
8900 Randers, DK-8900 Randers, Denmark. transmitted by aerosol between humans without a
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known animal reservoir. It invades endothelial cells Laboratory diagnosis of C. pneumoniae
and mononuclear lymphocytes, where it is converted
The diagnosis of C. pneumoniae infection can be es-into a non-infective reticulate body (RB) that replicates
tablished directly by detection of the whole organism,by binary fission in enlarging vacuoles called inclusion
its antigens, or its DNA, or indirectly by measuringbodies. The RBs again reorganise into EBs, which are
serum antibodies directed against the C. pneumoniaereleased by lysis of the cell, initiating a new cycle. In
organism. Both methods have several limitations.vitro, C. pneumoniae is able to multiply in vascular
endothelium, smooth muscle cells, and monocytes.
Direct detection (in plaques). Conventional light micro-The latter may cause dissemination from the airways
scopy can detect neither C. pneumoniae organisms norto the vascular endothelium. The duration of immune
C. pneumoniae inclusion bodies. The widely distributedprotection is limited4–6 and persistent infections may
enzyme-linked immunosorbent assay (ELISA) kits foroccur, since the host may be incapable of eradicating
detecting C. trachomatis LPS antigen can also detect C.the infection.4,6,7 However, it is unknown whether the
pneumoniae LPS antigen, but these tests lack sensitivityorganism causes occasional persistent or repeated in-
and specificity. Fluorescein-conjugated antibodiesfection, but both may cause intense inflammatory re-
against C. pneumoniae can also be used for microscopicactions.2
detection of C. pneumoniae antigen, as can immuno-
histochemical (IHC) antigen detection. However, the
diagnostic performance of those tests is unresolved.
Electron microscopy (EM) may reveal pear-shaped or
rounded EBs, but the area covered by EM is small and
Disease spectrum and epidemiology of C. pneumoniae an experienced observer is needed. The technique is
not useful for routine diagnosis. Isolation by culture
As already mentioned, C. pneumoniae causes upper is difficult both from respiratory samples and from
and lower respiratory infections, including more than atherosclerotic plaques. In fact, isolation from the latter
ten per cent of the cases of otitis media, pharyngitis, has succeeded only twice (Table 2).
bronchitis, and pneumonia.5,8 However, the number Various specific primers can detect C. pneumoniae
of studies is limited, especially concerning otitis media, DNA by polymerase chain reactions (PCR). Their
and there is considerable variation by region and time. specificity in respiratory samples is almost 100%, but
Furthermore, many infections may be asymptomatic the sensitivity is only about 75% when compared with
or subclinical. Chlamydia pneumoniae has also been serology.16 However, this is hardly true in ath-
described as a cause of endocarditis and myocarditis.9 erosclerotic plaques, because positive findings in ath-
The prevalence of infections varies from one region to erosclerotic lesions show poor reproducibility and
another; for instance, the Sami people in northernmost poor accordance with immunohistochemical antigen
Finland have a lower prevalence of antibodies against detection and EM. This may be due to substances
C. pneumoniae, compared with the remaining Finns.10 in human specimens that inhibit PCR, or to patchy
Such variation has also been detected between coun- occurrence of C. pneumoniae, or both. Furthermore,
tries, the highest seroprevalence occurring near the detection of C. pneumoniae antigens and DNA in lesions
equator in developing countries.8 is more frequent in persons with low rather than high
Infection with C. pneumoniae is endemic, but epi- titres.17 This observation is supported by combined
demics tend to occur every 2–3 years, followed by direct and indirect detection studies that showed lack
3–10 years with lower incidence.8,11 Infants are seldom of correlation between plaque positives and sero-
infected. The infection arises in pre-school children and positives.17–21 This suggests an individual variation of
young adolescents, and increases with age, reaching a humoral response to C. pneumoniae in the vascular
seroprevalence of 75% in the elderly. IgA antibody bed, or that persons with a high titre are more capable
titres usually decline and disappear three months after of eradicating C. pneumoniae from the atherosclerotic
infection. It has been suggested that a persistently plaques.
elevated level of IgA is indicative of chronic infection.
IgG antibodies may persist for years.5,8,12–14 Con- Indirect detection (in serum). The complement fixation
sequently, the increasing seroprevalence with age in- test (CF) is based on detection of antibodies against the
dicates that the majority of the population have two to common LPS antigen. It cannot, therefore, differentiate
three reinfections during their lifetime.15 For unknown between the various Chlamydia species, and is thus not
reasons, the seroprevalence is considerably higher in specific for C. pneumoniae infections. The sensitivity
regarding reinfections is low since it is usually negativemen than in women.2,8,14
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Table 1. Cross-sectional serological studies analysing the association between Chlamydia pneumoniae infection and atherosclerotic
manifestations.
Ref. Method Patients/ Disease Results
controls
12 MIF 70/41 Coronary AS* Significant increased IgG [128 and IgA [32
22 MIF 103/105 Coronary AS and AMI or Elevated titre was a risk factor for AMI or sudden death
sudden death during six months
23 CF 44/44 Coronary AS and AMI Significantly higher proportion with CF among diseased
24 MIF 461/95 Coronary AS by angiogram OR=2.0 (1.0–4.0) for coronary AS and IgG >60
25 MIF 171/120 Coronary AS by angiogram Summary OR=2.6 (1.4–4.8) for disease and raised IgG
51 MIF 100/64 Coronary AS or AMI Summary OR=6.9 (1.7–28.3) adjusting for age and risk factors
52 MIF 50/28 Coronary AS 75% cases and 93% controls with IgG >1:16
26 CF 46/46 Coronary AS Significantly higher proportion with CF among diseased
53 MIF 176/1518 Stroke or TCI Adjusted OR=4.4 and 4.2 in present/chronic and acute
infections, respectively
26 MIF 58/52 Stroke or TCI Raised IgA: 46.6% in pt. 23% in controls. Adjusted OR=1.7
AS=atherosclerosis; MIF=microimmunofluorescence test; CF=complement fixation test; OR=odds ratio; TCI=transient cerebral isch-
aemia.
in these cases.5 The microimmunofluorescence (MIF) independent risk factors for AMI during 6 months of
follow-up (OR=2.3 (1.3–5.4)).22test is specific for the species and allows detection of the
various immunoglobulin types against C. pneumoniae. Because of the seroepidemiological association, ef-
forts have been made to detect the organisms in theThe test requires experienced readers, and the exact
specificity and sensitivity of MIF are difficult to assess. tissues. In 1992, Shor et al.28 demonstrated C. pneu-
moniae-like organisms in coronary atheroscleroticA four-fold increase in IgG titre, or IgM titre [32,
approximately 3 weeks after onset indicates acute plaques by electron microscopy, and C. pneumoniae-
specific antigens by immunoperoxidase staining, butinfection. The increase in IgG titres may be delayed
until 8 weeks. The test is not suitable during the acute not in controls. Their study was expanded to include
polymerase chain reactions (PCR), and in 1993 theystate. IgG titres of 128–256 indicate past or pre-existing
infection. The persistence of the short-lived IgA may reported that 20 of 36 persons with coronary ath-
erosclerotic plaques contained C. pneumoniae, whilebe a better marker of chronic infections than IgG.22
IgM is not detectable in reinfections. none was detected in non-atherosclerotic plaques.18
Despite different diagnostic and technical methods, allIn summary, methods for direct and indirect de-
tection are not optimal for assessment of C. pneumoniae but two studies detected C. pneumoniae in 40–100% of
atherosclerotic plaques from coronary arteries, carotidinfection, or for the presence of C. pneumoniae in the
vascular bed. There is thus a need for improved arteries, and abdominal aortic aneurysms (AAA).18,28–34
Kuo et al.18 demonstrated C. pneumoniae in macro-methods than can reliably detect acute and chronic C.
pneumoniae infections and their presence in the vas- phages that made up the lipid core of atherosclerotic
plaques, and in smooth muscle cells, but not in normalcular bed.
tissue adjacent to the atherosclerotic lesions, nor in
normal artery controls. These studies clearly dem-
onstrate low agreement between the various methods
Seroepidemiology of C. pneumoniae applied on the same samples. Even when the same PCR
system was applied to the same sample by different
In 1988, Saikku et al.12 found that 50% of 40 males with research groups, the results differed. An explanation
acute myocardial infarction (AMI) and 68% of 30 males could be patchy occurrence of C. pneumoniae. Fur-
with angina pectoris, but only 17% of 41 matched thermore, attempts to culture C. pneumoniae have
controls had raised levels of IgG and IgA antibodies failed, except in two cases.35
against C. pneumoniae measured by MIF. Numerous
cross-sectional serological studies have since been
conducted, encompassing patients with athero-
sclerosis12,22–27 (Table 1). All these studies found in- Antibiotic intervention studies
creased levels of antibodies against C. pneumoniae,
compared with control groups, with odds ratios ran- Intervention studies have been conducted in order to
find out whether macrolide treatment of C. pneumoniaeging from 2.0 to 2.6. A prospective study reported that
raised IgA titre and circulating LPS-complexes were could improve the outcome of ischaemic heart disease.
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Table 2. Selected studies for Chlamydia pneumoniae detection in atherosclerotic lesions (AS), abdominal aortic aneurysms (AAA), and
sclerotic aortic valves.
Ref. Method Patients/ Disease Results
controls
18 IHC, PCR, EM 36/11 Coronary AS 56% positive patients, no positive controls*
30 PCR, EM, culture 72/28 Coronary AS 2% positive patients, 0% in controls. Not cultured
30 IHC 90/24 Coronary AS 79% positive patients, 4% positive controls
17 IHC 76/20 Carotid AS 54% positive patients, no positive control*
19 PCR 61/0 Carotid AS 15% positive*
54 IHC, PCR, culture 16/0 Carotid AS 68.8% positive, one cultured
31 IHC, PCR, culture 61/6 Carotid AS 59% positive. No positive controls. Not cultured
20 PCR 38/11 Stenotic aortic valves 49% positive patients, 9% positive controls*
2 IHC, PCR, EM 17/8 Stenotic aortic valves 53% positive patients, 12% positive controls
33 IHC 20/4 Aortic AS 30% positive patients, no positive controls
55 IHC, PCR 23/0 Femoral or popliteal AS 8 of 21 (38.1%) positive popliteal specimens
3 of 18 (16.7%) positive femoral specimens
56 PCR 40/40 AAA 35% positive AAA patients, 5% positive controls
57 PCR 20/0 Symptomatic AAA 0% positive
2 IHC, PCR, EM, Culture 12/3 AAA 100% positive, no positive controls. Not cultured
21 PCR 51/0 AAA 51% positive*
34 IHC 25/6 AAA 56% positive in AAA patients, none in controls
IHC=immunohistochemistry; PCR=polymerase chain reaction; EM=electron microscopy; AS=atherosclerosis. *No correlation between
PCR-positivity and seropositivity.
IgG antibody levels against C. pneumoniae were meas- and macrophages.38–40 When propagated in venous
endothelial cells, expression of tissue factor (Pro-ured in 220 men who had AMI 6 months to 10 years
previously.36 Sixty males had persistent IgG antibody coagulant) increased four-fold, and platelet adhesion
also increased. This could explain the associationlevels at 64 or above at re-measurement three months
later. These males were randomised into three groups: between thrombotic diseases and C. pneumoniae in-
fection. The tissue factor expression was enhanced(1) 500 mg azithromycin daily for three days (n=28);
(2) 500 mg azithromycin daily for three days, repeated even in the presence of tetracyline, suggesting that
the responsible chlamydial factor was preformed.40after three months (n=12); (3) placebo (n=20).
During the following 18 months, non-lethal AMI, A marked increase in the number of foam cells, and
accumulation of cholesterol esters, occurred when C.unstable angina or death caused by a cardiovascular
event were recorded. The risk of such events was pneumoniae was propagated in macrophages in the
presence of low-density lipoprotein (LDL). The foampositively correlated with the IgG antibody titre
against C. pneumoniae; 7% in patients with no detectable cell formation was not inhibited by the antioxidants
antibodies, 15% in those with a low IgG antibody titre butylated hydroxytoluene or fucoidan, suggesting
(<64), and 128% in those with high AB-titre and placebo that lipid accumulation did not involve scavenger
treatment, but only 8% in the groups treated with receptors. Heparin, which blocks binding of LDL to
antibiotics (OR=4.2 95% CI: 1.2–15.5). the LDL-receptor, inhibited the C. pneumoniae-induced
A multicentre trial in Argentina37 randomised 202 foam cell formation, suggesting that the pathogen
patients with unstable angina or non Q-wave AMI to induced lipid accumulation by dysregulating native
roxithromycin (a macrolide) 150 mg twice daily for LDL uptake or metabolism, or both.41 Serologically
one month (n=102), or placebo (n=100). During fol- confirmed chronic infection with C. pneumoniae is
low-up, there were no deaths in the intervention group associated with increased levels of triglycerides and
and none experienced AMI, though 1.1% had recurrent total cholesterol, and a decreased ratio of high
angina pectoris, while in the placebo group 5.4% ex- density lipoprotein/total cholesterol.42 Intranasal in-
perienced recurrent angina pectoris, 2.2% AMI, and oculation of New Zealand white rabbits with C.
2.2% died of ischaemic heart disease (p<0.05). pneumoniae accelerates intimal thickening in the rab-
bits when they are on a normal diet43 or one that
is modestly cholesterol-enhanced,44 while weekly
treatment with azithromycin after inoculation pre-Possible effects on the vascular system
vented this acceleration.44 Maass and Gieffers,45 using
immunoblot profiles, observed that IgG seroresponsesIn vitro studies have shown that C. pneumoniae may
replicate in endothelial cells, smooth muscle cells, to 40, 54, 60, 75, and 98 kDa C. pneumoniae antigens
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were more frequent in seropositive atherosclerotic C. pneumoniae organisms may be inactive. However,
if they were metabolically inactive, macrolides,patients than in seropositive patients without athero-
sclerosis. Puolakkainen et al.46 reported that re- which inhibit protein synthesis, should not be
effective. The presence of the bacteria in the vesselactivities with 42 and 52-kDa C. pneumoniae antigens
were more frequent in seropositive atherosclerotic walls might be a consequence of phagocytosis by
macrophages from other anatomical regions in thepatients than in seropositive normal patients with
acute respiratory infection. These two reports suggest organism, and random migration to atherosclerotic
vessels as part of the infiltration. On the otherthat the effect of C. pneumoniae in the pathogenesis
of atherosclerosis may be caused by certain strains. hand, culture of C. pneumoniae is difficult, and
Koch’s postulates do not encompass unculturable
organisms, e.g. Tropheryma whippeli, the cause of
Whipple’s disease. Koch’s postulates are not ful-
Discussion filled in many other infectious diseases, e.g. leprosy
and syphilis. The evidence that these diseases are
Atherosclerosis seems to be preceded by damage infections is based on improvement after antibiotic
of the endothelium. Chlamydia pneumoniae is able treatment. With the recent introduction of animal
to multiply in vascular endothelium, and it has models,47,48 clarification regarding C. pneumoniae,
been detected in human atherosclerotic lesions. atherosclerosis, and Koch’s postulates now seems
The known presence of foam cells, fatty streaks, within reach.
and other initial atherosclerotic lesions from early The results of the two independent intervention
adulthood could be a consequence of the high studies are at present the strongest indicators for an
incidence of infections in late childhood. Infections active role of C. pneumoniae in coronary athero-
are not uncommon in the temperate zones, but sclerosis, but the numbers of patients were small, and
the predominance of infections near the equator, the periods of follow-up very short. The positive cor-
and the finding of a higher prevalence of sero- relation between antibody levels and risk of cardio-
positivity in Afro-Caribbeans and Asians than in vascular event is a strong additional indication. On
Whites, does not correspond with a disease that the other hand, one could claim that the effect was
mainly affects the population in the western world. caused by the non-specific anti-inflammatory effect
The male predominance of seropositivity and or antioxidative effect of the macrolide, which is well
atherosclerosis corresponds well, but the increasing known for this group of antibiotics.49 However, re-
frequency of atherosclerosis in females suggests gardless of mechanism of action, the potential benefits
that other causes of atherosclerosis are present. of antimicrobial chemotherapy of atherosclerotic ma-
Nevertheless, C. pneumoniae is present in ath- nifestations that have been demonstrated in animal44
erosclerotic lesions. It is still unknown whether and human intervention studies36,37 are encouraging.
this is a harmless finding, caused by damaged Research in the future must concentrate on better
vascular tissue, or an active infection triggering methods for detecting C. pneumoniae, in order to
the immune system. evaluate the impact of this organism on ath-
Koch postulated four demands that should be erosclerotic manifestations, and to distinguish in-
fulfilled before a disease was proved infectious: fected from uninfected individuals. In parallel, the
(i) the micro-organism is always present in the impact of macrolides on the outcome of ath-
diseased tissue; (ii) the micro-organism can be erosclerotic manifestations should be clarified in
cultured; (iii) the cultured micro-organism is cap- large randomised controlled clinical intervention tri-
able of producing typical manifestations in suitable als. Such trials are urgently needed: first, because a
animals after inoculation; (iv) the micro-organism new strategy for treating serious major health prob-
is detectable in the pathological tissue from the lem using antibiotics might be effective; second,
animal. because there is a risk of non-documented wide-
According to these postulates and present know- spread treatment, and of ethical problems in ac-
ledge, atherosclerosis cannot be recognised as an cepting placebo-controlled trials.50
infectious disease. Chlamydia pneumoniae is not
always present in pathological tissue. This may be Future antibiotic trials
due to insensitive detection methods or patchy
distribution in the tissue; diagnostic methods need Lower limb atherosclerosis is often associated with
severe, widespread atherosclerosis including the cor-to be improved. The failure to culture C. pneumoniae
from atherosclerotic plaques suggests that detected onary and cerebral vessels. Consequently, one may
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5 Saikku P. The epidemiology and significance of Chlamydia pneu-argue that the chronic lower limb atherosclerosis is too
moniae. J Infect 1992; 25: 27–35.extensive to expect benefit from antibiotic treatment. 6 Grayston JT, Wang SP, Yeh LJ, Kuo CC. Importance of re-
However, the animal study suggests that further pro- infection in the pathogenesis of trachoma. Rev Infect Dis 1985; 7:
717–725.gression could be lessened. If so, conservative treat-
7 Beatty WL, Byrne GI, Morrison RP. Repeated and persistentment of intermittent claudication combined with infection with Chlamydia and the development of chronic in-
antibiotic treatment may prevent surgery, and treat- flammation and disease. Trends Microbiol 1994; 2: 94–98.
8 Grayston JT, Campbell LA, Kuo CC et al. A new respiratoryment of operated patients may prevent further surgery
tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Disbecause of atherosclerotic progression. The mortality 1990; 161: 618–625.
of patients with lower limb atherosclerosis is high 9 Odeh M, Oliven A. Chlamydial infections of the heart. Eur J
Clin Microbial Infect Dis 1992; 11: 885–893.because of the risk of death due to cardiac or cerebral
10 Laurila A, Bloigu A, Nayha S et al. Chlamydia pneumoniae andatherosclerosis. Consequently, overall survival may Helicobacter pylori infections in Sami and Finnish herders. Int J
also be improved by antibiotic treatment. Circumpolar Health 1997; 56: 70–75.
11 Karvonen M, Toumilehto J, Pitkaniemi J, Saikku P. The epi-In Viborg County in Denmark, randomised anti-
demic cycle of Chlamydia pneumoniae infection in eastern Finland.biotic intervention trials are planned to start in the
Epid Infect 1993; 110: 349–360.
autumn of 1998 concerning the secondary and tertiary 12 Saikku P, Leinonen M, Matilla K. Serological evidence of an
association of a novel Chlamydia, TWAR, with chronical cor-prophylaxis of 1000 patients with lower limb athero-
onary heart disease and acute myocardial infarction. Lancet 1988;sclerosis. At present, primary antibiotic prophylaxis
2: 983–986.
of persons without any symptoms seems unjustified, 13 Aldous MB, Grayston JT, Wang SP, Foy HM. Seroepidemiology
of Chlamydia pneumoniae TWAR infection in Seattle families,because no risk has been identified. Thus, primary
1966–1979. J Infect Dis 1992; 166: 646–649.prophylaxis would have to be offered to everybody,
14 Kuo CC, Jackson LA, Campbell LA, Grayston JT. Chlamydia
with significant financial and ecological consequences. pneumoniae (TWAR). Clin Microbiol Rev 1995; 8: 451–461.
15 Østergaard L, Møller JK, Birkelund S, Christiansen G,A register study of all 30000 50–70-year-old inhabitants
Anderson PL. Development of a nested polymerase chain re-in Aarhus County in Denmark concerning primary
action using time resolved fluorometry for automated detectionprophylaxis has therefore been started. of Chlamydia trachomatis. Immunology & Infectious Diseases 1994;
The risk of stroke and carotid stenosis is associated 4: 36–40.
16 Thom DH, Grayston JT, Campbell LA et al. Respiratory in-with chlamydial seropositivity, and C. pneumoniae is
fection with Chlamydia pneumoniae in middle aged and olderfrequently detected in plaques of carotid stenosis. adult outpatients. Eur J Clin Microbiol Infect Dis 1994; 13: 785–792.
Patients with asymptomatic stenoses and stenoses less 17 Chiu B, Viira E, Tucker W, Fong IW. Chlamydia pneumoniae,
cytomegalovirus, and Herpes simplex virus in atherosclerosis ofthan 70% experience minor, if any, benefit from surgery
the carotid artery. Circulation 1997; 96: 2144–2148.because of the risk of peroperative stroke. They may 18 Kuo CC, Shor A, Campbell LA et al. Demonstration of Chlamydia
benefit from antibiotic treatment concerning embolus pneumoniae in arteriosclerotic lesions of coronary arteries. J Infect
Dis 1993; 167: 841–849.formation and atherosclerotic progression. Patients
19 Maas M, Krause E, Engel PM, Kruger S. Endovascular pres-with small AAA are seldom offered an operation ence of Chlamydia pneumoniae in patients with hemodynamically
because of the low risk of rupture, but a considerable effective carotid artery stenosis. Angio 1997; 48: 699–706.
20 Nystrom-Rosander C, Thelin S, Hjelm E et al. High incidenceproportion of these expand to dimensions that carry
of Chlamydia pneumoniae in sclerotic heart valves of patientsa high risk of rupture. Consequently, they are offered undergoing aortic valve replacement. Scand J Infect Dis 1997; 29:
observation, and operation when indicated. Antibiotic 361–365.
21 Blasi F, Denti F, Erba M et al. Detection of Chlamydia pneumoniaetreatment may lessen further expansion and prevent
but not Helicobacter pylori in arteriosclerotic plaques of aorticlater operation. In Viborg County, a randomised anti-
aneurysms. J Clin Microbiol 1996; 34: 2766–2769.
biotic intervention trial of 150 small AAA, diagnosed 22 Saikku P, Leinonen M, Tenkanen L et al. Chronic Chlamydia
pneumoniae infection as a risk factor for coronary heart diseaseat screening, has begun.
in the Helsinki Heart Study. Ann Intern Med 1992; 116: 273–278.
23 Leinonen M, Linnanma¨ki E, Matilla K. Circulating immune
complexes containing chlamydial lipopolysaccharide in acute
myocardial infarction. Microb Pathog 1990; 9: 67–73.
24 Thom DH, Wang S, Grayston JT, Siscovick DS, Stewart DK.
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